Fig. 4: Response to dual BCR and PARP inhibition of 38 CLL primary samples in the presence of stromal stimulation. | Leukemia

Fig. 4: Response to dual BCR and PARP inhibition of 38 CLL primary samples in the presence of stromal stimulation.

From: CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition

Fig. 4

a, b Primary CLL cells were seeded in co-culture with HS-5 bone marrow stromal cells, 1.5 μg/mL CpG and 50 ng/mL IL-2 and treated with olaparib (5 μM), ibrutinib (1 μM) or the combination of both for 5 days. Normalized surviving fraction is expressed relative to untreated cells. Data are presented as the mean ± SD of del(11q) (n = 15) vs. non del(11q) (n = 23) (a) or ATMWT (n = 20); ATM monoallelic defective (n = 11) and ATM biallelic defective (n = 7) CLL cases (b). c Response of primary CLL cells (n = 38) to the combination of olaparib (5 μM) and ibrutinib (1 μM) based on cytogenetics, IGHV mutational status and mutations in known CLL driver genes. Cells were seeded in co-culture with HS-5 bone marrow stromal cells, 1.5 μg/mL CpG and 50 ng/mL IL-2 and treated with the drug combination for 5 days.

Back to article page